NCT01596413 2024-07-26
Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years
Kyowa Kirin Co., Ltd.
Phase 1 Withdrawn
Clinical Trials
5 trialsNCT01596426 2024-07-26
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years
Kyowa Kirin Co., Ltd.
Phase 1 Withdrawn
NCT01596400 2024-06-17
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years
Kyowa Kirin Co., Ltd.
Phase 1 Completed
NCT03333824 2019-03-25
Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer
AstraZeneca
Phase 1 Completed
NCT02563951 2016-01-08
Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers
Maxinase Life Sciences Ltd.
Phase 1 Completed